# An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

> **NCT05867147** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 56 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Vanzacaftor
- **DRUG:** Vanzacaftor Placebo
- **DRUG:** Moxifloxacin
- **DRUG:** Moxifloxacin Placebo

## Key facts

- **NCT ID:** NCT05867147
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-26
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867147, "An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05867147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*